InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,712.69
(
-0.28%
)
US TECH 100
19,512.00
(
0.37%
)
Dow Jones
41,794.60
(
-0.61%
)
Brent Oil
75.43
(
0.41%
)
Bitcoin
68,834.69
(
1.50%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

gdollasign

Send PM Follow Ignore
Followers 6
Posts 973
Boards Moderated 0
Alias Born 06/08/2010

gdollasign

Re: None

Wednesday, 10/16/2013 1:34:12 PM

Wednesday, October 16, 2013 1:34:12 PM

Post# of 80490
From Ariad Change in Iclusig development PR:

The Company is implementing the following actions in its Iclusig clinical development program:

http://investor.ariad.com/phoenix.zhtml?c=118422&p=irol-newsArticle&ID=1862864&highlight=


excerpt: .....subject to agreement with the FDA, will be resumed with anticipated changes in dose and other modifications

I find there are some telling words in the PR. Worth an additional read imo.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up